
    
      This study was a 60-month prospective, multicenter, observational study of adalimumab in
      adult participants with CD who resided in Germany. Visits were scheduled every 3 months for
      the first year and every 6 months thereafter. Participants continued in the study for a
      maximum of 60 months or until discontinuation from adalimumab therapy.
    
  